CV & Diabetes Market Forecast

CV & Diabetes Market Forecast published by Datamonitor in January, 2009. This report price starts from US $ 15200.

Introduction

Abstract

Introduction

Datamonitor expects antidiabetic therapies to emerge as the biggest revenue earner in the cardiovascular and metabolic markets by 2017. A large and diverse development pipeline will provide a number of new blockbuster drugs but the heavy genericization of the hypertension and dyslipidemia primary care markets will lead to the overall market only growing by 0.9% in the seven major markets.

Key reasons to purchase this research

• A detailed clinical and commercial assessment of all key cardiovascular and metabolic therapy areas.
• An analysis of the portfolios of top 10 leading cardiovascular and metabolic companies.
• Sales based sales forecasts for all key cardiovascular and metabolic active agents in the seven major markets to 2017.

Table of Contents

OVERVIEW

• This product contains forecasts for the cardiovascular and metabolic therapies across the seven major markets from 2008 to 2017. It has been designed for delivery in an excel data pack format, but for more detail about this disease area please see the accompanying Commercial Insight: DMHC2420 word document and PowerPoint executive presentation.
  • The associated report can be found under Latest research in the Knowledge centre, through the search function or by contacting your sales representative.
  • Please select the data pack option from the download menu at the side of the page to access the model.
• Scope of the analysis
• Datamonitor insight into the cardiovascular market
• Forecasting Methodology
  • The forecasting model:
  • General event information:
  • Event selection and quantification:
  • Event parameters:

Related Reports